Cargando…

Population Pharmacokinetics of Sifalimumab, an Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus

BACKGROUND AND OBJECTIVES: Sifalimumab is a fully human immunoglobulin G1κ monoclonal antibody that binds to and neutralizes a majority of the subtypes of human interferon-α. Sifalimumab is being evaluated as a treatment for systemic lupus erythematosus (SLE). The primary objectives of this analysis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Narwal, Rajesh, Roskos, Lorin K., Robbie, Gabriel J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2013
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824374/ https://www.ncbi.nlm.nih.gov/pubmed/23754736 http://dx.doi.org/10.1007/s40262-013-0085-2

Ejemplares similares

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
por: Khamashta, Munther, et al.
Publicado: (2016)

Structural Insights into the Neutralization Properties of the Fully Human, Anti-interferon Monoclonal Antibody Sifalimumab
por: Oganesyan, Vaheh, et al.
Publicado: (2015)

Sifalimumab, a Human Anti–Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study: A Phase I Randomized, Controlled, Dose-Escalation Study
por: Petri, Michelle, et al.
Publicado: (2013)

Efficacy of sifalimumab for treatment of skin injury caused by systemic lupus erythematosus
por: Huo, Ai-xin, et al.
Publicado: (2019)

Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus
por: Yao, Yihong, et al.
Publicado: (2010)

Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
por: Furie, Richard, et al.
Publicado: (2017)

Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis
por: Guo, Xiang, et al.
Publicado: (2014)

Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus
por: Almquist, Joachim, et al.
Publicado: (2022)

Monoclonal Antibodies for Systemic Lupus Erythematosus (SLE) †
por: Ponticelli, Claudio, et al.
Publicado: (2010)

A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
por: Higgs, Brandon W, et al.
Publicado: (2014)

Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis
por: Boedigheimer, Michael J, et al.
Publicado: (2017)

Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus
por: Yao, Yihong, et al.
Publicado: (2009)

Systematic Review: Monoclonal Antibody-Induced Subacute Cutaneous Lupus Erythematosus
por: Bolton, Chrissy, et al.
Publicado: (2020)

Mechanistic modeling of a human IgG(4) monoclonal antibody (tralokinumab) Fab‐arm exchange with endogenous IgG(4) in healthy volunteers
por: Wang, Bing, et al.
Publicado: (2022)

Interferon Alpha in Systemic Lupus Erythematosus
por: Niewold, Timothy B., et al.
Publicado: (2010)

A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition
por: Gong, Chang, et al.
Publicado: (2017)

Characterisation of anti‐alpha toxin antibody levels and colonisation status after administration of an investigational human monoclonal antibody, MEDI4893, against Staphylococcus aureus alpha toxin
por: Ruzin, Alexey, et al.
Publicado: (2018)

Interferon targeted therapies in systemic lupus erythematosus
por: Misra, Durga Prasanna, et al.
Publicado: (2017)

Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status
por: Baverel, Paul G., et al.
Publicado: (2018)

Pharmacokinetics of Monoclonal Antibodies
por: Ryman, Josiah T., et al.
Publicado: (2017)

Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus
por: Dimelow, Richard, et al.
Publicado: (2020)

Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults
por: Yu, Xiang-Qing, et al.
Publicado: (2016)

In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model
por: Wang, Hanwen, et al.
Publicado: (2019)

Health Technology Assessment of Belimumab: A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
por: Specchia, Maria Lucia, et al.
Publicado: (2014)

Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood
por: Bennett, Lynda, et al.
Publicado: (2003)

Systemic lupus erythematosus and the type I interferon system
por: Rönnblom, Lars, et al.
Publicado: (2003)

Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus
por: Riggs, Jeffrey M, et al.
Publicado: (2018)

Clinical and serological manifestations associated with interferon-α levels in childhood-onset systemic lupus erythematosus
por: Postal, Mariana, et al.
Publicado: (2012)

Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma
por: Yan, Li, et al.
Publicado: (2019)

Anti-TNF-α Therapies in Systemic Lupus Erythematosus
por: Zhu, Lang-Jing, et al.
Publicado: (2010)

Exposure–Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status
por: Baverel, Paul, et al.
Publicado: (2019)

Anti-IL-10 antibody in systemic lupus erythematosus
por: Uchida, Marina, et al.
Publicado: (2019)

A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma
por: Singh, Dave, et al.
Publicado: (2010)

Unraveling the Link between Interferon-α and Systemic Lupus Erythematosus: From the Molecular Mechanisms to Target Therapies
por: Infante, Barbara, et al.
Publicado: (2022)

A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer
por: Jafarnejad, Mohammad, et al.
Publicado: (2019)

A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade
por: Milberg, Oleg, et al.
Publicado: (2019)

Interferon Regulatory Factor 5 in the Pathogenesis of Systemic Lupus Erythematosus
por: Cham, Candace M., et al.
Publicado: (2012)

A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors
por: Becerra, Carlos R., et al.
Publicado: (2014)

Association between anti-interferon-alpha autoantibodies and COVID-19 in systemic lupus erythematosus
por: Gupta, Sarthak, et al.
Publicado: (2020)

Periodontitis is associated with disease severity and anti-double stranded DNA antibody and interferon-gamma levels in patients with systemic lupus erythematosus
por: Gofur, Nanda R.P., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_il2qvq4t4qag3evbidem3sb30a